At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 68 enrolled

Drug / intervention

Erlotinib +3 moredrug

Likely dose

Erlotinib 150 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00563784

NCT00563784Phase 2Completed

Compare CT.gov

A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center·interventional·Posted Nov 26, 2007·Updated Nov 20, 2019

In Brief

A Phase 2 clinical trial evaluating Erlotinib, Carboplatin, and 2 other interventions for Non-Small Cell Lung Cancer and Lung Cancer. Completed, enrolled 68 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-Small Cell Lung Cancer, Lung Cancer

CountriesUnited States

CollaboratorsGenentech, Inc., United States Department of Defense

Timeline

Phase 2CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartNov 2007

First PostedNov 2007

Primary CompletionMay 2018

TodayJul 2026

First PostedNov 26, 2007

Enrollment StartNov 1, 2007

Primary CompletionMay 30, 2018

TodayJul 2, 2026

Enrollment to primary: 10.6 yearsPosted 18.6 years ago

Interventions

Erlotinibdrug

150 mg by mouth daily for 7 Weeks

Carboplatindrug

2 AUC by vein weekly for 7 Weeks

Paclitaxeldrug

45 mg/m\^2 by vein weekly for 7 Weeks

Radiation Therapyradiation

63 GY/35 fractions for 7 weeks (+/- 5 days)